AbbVie's Rinvoq EU Approval in pJIA Adds Pediatric Indication, Consistent with Growth Thesis

What happened

AbbVie's Rinvoq has received EU approval for polyarticular juvenile idiopathic arthritis (pJIA), expanding its reach into pediatric patients and adding to its portfolio of immuno-inflammatory indications. This approval potentially supports the pediatric exclusivity condition critical to Rinvoq's U.S. patent settlement extending potential exclusivity to April 2037. The news is positive but incremental, as Rinvoq already anchors AbbVie's growth along with Skyrizi, together accounting for ~42% of 2025 revenues. The stock currently trades at $224.81, near our base case fair value of $235, leaving limited margin of safety given concentration and policy risks. Investors should continue to focus on quarterly execution against the 2026 immunology framework and watch for any signs of pricing or access pressure.

Implication

The added pediatric indication may strengthen Rinvoq's exclusivity and revenue durability, but the market already prices in strong Rinvoq growth, so the news is unlikely to move the needle. AbbVie still must prove that Skyrizi and Rinvoq can hit the 2026 immunology target of $34.5B while managing low-single-digit pricing headwinds and the ~$3.5B Skyrizi royalty drag. Aesthetics remains a swing factor with Juvederm down double digits, and IRA negotiations on Botox are a known overhang. We maintain our WAIT stance and would look to add near the $210 entry point if a broader market pullback or disappointing quarterly data provides an opportunity. The upcoming earnings call will be critical to validate the 2026 guidance and share-capture metrics.

Thesis delta

The EU approval for Rinvoq in pJIA is consistent with the existing thesis that Rinvoq can extend its economic duration, but it does not alter our valuation or risk assessment. Our base case value of $235 remains intact, and the approval may marginally increase confidence in Rinvoq's long-term growth, but it doesn't change the need for confirmation of near-term execution. We see no reason to change the WAIT rating or the $210 attractive entry point.